Jazz Pharmaceuticals Plc Stock Price, News & Analysis

Jazz Pharmaceuticals will present seven abstracts at the ASCO Annual Meeting from June 3-7, 2022, and eight at the EHA Congress from June 9-12, 2022. Key data includes findings on Rylaze in treating acute lymphoblastic leukemia and lymphoblastic lymphoma. An oral presentation will cover the efficacy and safety of Rylaze administered intramuscularly, while several posters will feature data on Zepzelca, Vyxeos, and other therapies. The presentations reflect Jazz's commitment to addressing unmet patient needs in oncology through research advancement.

Axsome Therapeutics has completed the U.S. acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals, enhancing its CNS product portfolio. Sunosi, approved by the FDA for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, boasts broad insurance coverage for 96% of commercial lives. The acquisition positions Axsome as a commercial neuroscience company, supporting patient access through comprehensive affordability programs. Clinical trials have shown significant efficacy for Sunosi, including up to 22% reduction in daytime sleepiness and increased wakefulness. Axsome plans further research into Sunosi.

Jazz Pharmaceuticals has successfully completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics for an upfront payment of $53 million. Jazz will receive royalties of high single-digit on U.S. net sales for current indications and mid-single-digit for future indications. This transaction allows Jazz to focus on strategic areas for sustainable growth, as stated by CEO Bruce Cozadd. The ex-U.S. transaction is expected to close within 60 days, enhancing Jazz's commitment to operational excellence and shareholder value.

Jazz Pharmaceuticals (JAZZ) announced strong financial results for Q1 2022, reporting $813.7 million in total revenues, a 34% increase year-over-year. The company raised its full-year revenue guidance to $3.5 to $3.7 billion, citing momentum from recent product launches like Xywav for narcolepsy and idiopathic hypersomnia. The net income was $1.6 million ($0.03 per share), significantly lower than $121.8 million from a year earlier. Strategic divestitures and new product developments are set to enhance the company's focus and long-term value.

Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize DSP-0187 in the U.S., Europe, and other regions through a licensing agreement with Sumitomo Pharma. The agreement includes a $50 million upfront payment and up to $1.09 billion in milestone payments. Jazz aims to expedite the development of DSP-0187, a novel oral orexin-2 receptor agonist for treating narcolepsy and other sleep disorders. This collaboration aligns with Jazz's commitment to innovation in sleep medicine, leveraging its expertise in delivering therapies that enhance patient care.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in the BofA Securities 2022 Global Healthcare Conference on May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. ET in Las Vegas. An audio webcast will be available on the Investor section of their website, with a replay archived for 30 days. Jazz Pharmaceuticals is dedicated to developing innovative medicines in neuroscience and oncology, serving patients in nearly 75 countries. For more details, visit www.jazzpharmaceuticals.com.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will report its 2022 first quarter financial results on May 4, 2022, after U.S. market close. Management will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The U.S. and international dial-in numbers for the conference call are provided. A replay will be available until May 11, 2022. Jazz Pharmaceuticals focuses on developing innovative medicines for serious diseases, maintaining a diverse portfolio of marketed medicines and product candidates in neuroscience and oncology.

Jazz Pharmaceuticals presented promising pre-clinical data for its investigational drug JZP815 at the AACR Annual Meeting. The pan-RAF kinase inhibitor showed effectiveness in inhibiting tumor growth in various RAS- and BRAF-mutated solid tumor models and enhanced activity when combined with other MAPK inhibitors. Jazz plans to submit an IND for JZP815 this year, targeting challenging cancers like colorectal and non-small cell lung cancer. The drug's unique mechanism minimizes paradoxical pathway activation, potentially addressing unmet medical needs.

Jazz Pharmaceuticals has entered a licensing agreement with Werewolf Therapeutics for WTX-613, an innovative immuno-oncology therapy. Jazz will pay $15 million upfront, with up to $1.26 billion in potential milestone payments. WTX-613 aims to enhance cancer treatment by minimizing systemic toxicity associated with conventional therapies. This program expands Jazz's oncology pipeline, with an IND application planned for submission in 2023. Both companies express optimism about the collaboration and the future potential of WTX-613 in treating various cancers.